The effect of dexrazoxane (ICRF-187) on doxorubicin- and daunorubicin-mediated growth inhibition of Chinese hamster ovary cells

Anti-Cancer Drugs

Volumn 7, Issue 5, 1996, Pages 558-567

  Hasinoff, Brian B ^a   Yalowich, Jack C ^b   Ling, Yangzhi ^a   Buss, Joan L ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

antagonism; cytotoxicity; daunorubicin; dexrazoxane; doxorubicin; topoisome rase II

Indexed keywords

2,3 BIS(3,5 DIOXO 1 PIPERAZINYL)BUTANE; ANTHRACYCLINE DERIVATIVE; DAUNORUBICIN; DOXORUBICIN; RAZOXANE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CHO CELL; CONTROLLED STUDY; DRUG ANTAGONISM; GROWTH INHIBITION; NONHUMAN; PRIORITY JOURNAL;

EID: 0029796045     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199607000-00011     Document Type: Article

References (42)

1. Speyer JL, Green MD, Zeleniuch-Jacquotte A, et al. ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol 1992; 10: 117-27.
2. Koning J, Palmer P, Franks CR, et al. Cardioxane-ICRF-187, towards anticancer drug specificity through selective toxicity reduction. Cancer Treat Rev 1991; 18: 1-19.
3. Anon. Dexrazoxane for cardiac protection against doxorubicin. Med Lett Drugs Ther 1995; 37: 109-11.
4. Hasinoff BB. Pharmacodynamics of the hydrolysis-activation of the cardioprotective agent (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane. J Pharm Sci 1994; 83: 64-7.
5. Hasinoff BB. An HPLC and spectrophotometric study of the hydrolysis of ICRF-187 (dexrazoxane, (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane) and its one-ring opened intermediates. Int J Pharm 1994; 107: 67-76.
6. Huang Z-X, May PM, Quinlan KM, Williams DR, Creighton AM. Metal binding by pharmaceuticals. Part 2. Interactions of Ca(II), Cu(II), Fe(II), Mg(II), Mn(II) and Zn(II) with the intracellular hydrolysis products of the antitumor agent ICRF-159 and its inactive homologue ICRF-192. Agents Actions 1982; 12: 536-42.
7. Buss JL, Hasinoff BB. The one-ring open hydrolysis product intermediates of the cardioprotective agent ICRF-187 (dexrazoxane) displace iron from iron-anthracycline complexes. Agents Actions 1993; 40: 86-95.
8. Hasinoff BB. NADPH-cytochrome-P450 reductase promotes hydroxyl radical production by the iron complex of ADR-925, the hydrolysis product of ICRF-187 (dexrazoxane). Free Rad Res 1995; 22: 319-25.
9. Creighton AM, Hellmann K, Whitecross S. Antitumour activity in a series of bisdiketopiperazines. Nature 1969; 22: 384-5.
10. Witiak DT, Wei Y. Dioxopiperazines: chemistry and biology. Prog Drug Res 1991; 35: 249-363.
11. Tanabe K, Ikegami Y, Ishida R, Andoh T. Inhibition of topoisomerase II by antitumor agents bis(2,6-dioxopiperazine) derivatives. Cancer Res 1991; 51: 4903-8.
12. Ishida R, Miki T, Narita T, et al. Inhibition of intracellular topoisomerase II by antitumor bis(2,6-dioxopiperazine) derivatives: mode of cell growth inhibition distinct from that of cleavable complex-forming type inhibitors. Cancer Res 1991; 51: 4909-16.
13. Hasinoff BB, Kuschak TI, Yalowich JC, Creighton AM. A QSAR study comparing the cytotoxicity and DNA topoisomerase II inhibitory effects of bisdioxopiperazine analogs of ICRF-187 (dexrazoxane). Biochem Pharmacol 1995; 50: 953-8.
14. Corbett AH, Osheroff N. When good enzymes go bad: conversion of topoisomerase II to a cellular toxin by antineoplastic drugs. Chem Res Toxicol 1993; 6: 585-97.
15. Tewey KM, Rowe TC, Yang L, Halligan BD, Liu LF. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 1984; 226: 466-8.
16. Bodley A, Liu LF, Israel M, et al. DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA. Cancer Res 1989; 49: 5969-78.
17. D'Arpa P, Liu LF. Topoisomerase-targeting antitumor drugs. Biochim Biophys Acta 1989; 989: 163-77.
18. Glisson BS, Ross WE. DNA topoisomerase II: a primer on the enzyme and its unique role as a multidrug target in cancer chemotherapy. Pharmacol Ther 1987; 32: 89-106.
19. Bojanowski K, Lelievre S, Markovits J, Couprie J, Jacquemin-Sablon A, Larsen AK. Suramin is an inhibitor of DNA topoisomerase II in vitro and in Chinese hamster fibrosarcoma cells. Proc Natl Acad Sci USA 1992; 89: 3025-9.
20. Drake FH, Hofman GA, Mong SM, et al. In vitro and intracellular inhibition of topoisomerase II by the antitumor agent merbarone. Cancer Res 1989; 49: 2578-83.
21. Jensen PB, Jensen PS, Demant EJF, et al. Antagonistic effect of aclarubicin on daunorubicin-induced cytotoxicity in human small cell lung cancer cells: relationship to DNA integrity and topoisomerase II. Cancer Res 1991; 51: 5093-9.
22. Sehested M, Jensen PB, Sorensen BS, Holm B, Friche E, Demant EJF. Antagonistic effect of the cardioprotector (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) on DNA breaks and cytotoxicity induced by the topoisomerase II directed drugs daunorubicin and etoposide (VP-16). Biochem Pharmacol 1993; 46: 389-93.
23. Roca J, Ishida R, Berger JM, Andoh T, Wang JC. Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed protein clamp. Proc Natl Acad Sci USA 1994; 91: 1781-5.
24. Supino R. Influence of ICRF-159 or ICRF-186 on cytotoxicity of daunorubicin and doxorubicin. Tumori 1984; 70: 121-6.
25. Kano Y, Narita T, Suzuki K, et al. The effects of ICRF-154 in combination with other anticancer agents in vitro. Br J Cancer 1992; 66: 281-6.
26. Wadler S, Green MD, Muggia FM. Synergistic activity of doxorubicin and bisdioxopiperazine (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) against the murine sarcoma S180 cell line. Cancer Res 1986; 46: 1176-81.
27. Wadler S, Green MD, Basch R, Muggia FM. Lethal and sublethal effects of the combination of doxorubicin and the bisdioxopiperazine, (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane ICRF-187, on murine sarcoma S180 in vitro. Biochem Pharmacol 1987; 36: 1495-501.
28. Scambia G, Bitta RD, Panici PB, et al. Bisdioxopiperazine, (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane, (ICRF-187), enhances the antiproliferative effect of cisplatin on human ovarian cancer cells. Gynecol Oncol 1995; 57: 16-22.
29. Marks DC, Belov L, Davey MW, Davey RD, Kidman AD. The MTT cell viability assay for cytotoxicity testing in multidrug-resistant human leukemic cells. Leuk Res 1992; 16: 1165-73.
30. Creighton AM. Bis diketopiperazines. US Patent 3,941,790. 2 March, 1976.
31. Fisher GR, Patterson LH. Lack of involvement of reactive oxygen in the cytotoxicity of mitoxantrone, CI941 and ametantrone in MCF-7 cells: comparison with doxorubicin. Cancer Chemother Pharmacol 1992; 30: 451-8.
32. Barranco SC. Cellular and molecular effects of adriamycin on dividing and nondividing cells. Pharmacol Ther 1984; 24: 303-19.
33. Stephens TC. An investigation of the effects of the antitumor agent ICRF 159 on the growth of BHK-21S cells in culture. PhD Thesis, University of London, London 1974: 159.
34. Dawson KM. Studies on the stability and cellular distribution of dioxopiperazines in cultured BHK-21S cells. Biochem Pharmacol 1975; 24: 2249-53.
35. Minderman H, Linssen P, Wessels J, Haanen C. Cell cycle related uptake, retention and toxicity of idarubicin, daunorubicin and doxorubicin. Anticancer Res 1993; 13: 1161-6.
36. Capranico G, Soranzo C, Zunino F. Single-strand DNA breaks induced by chromophore-modified anthracyclines in P388 leukemia cells. Cancer Res 1986; 46: 5499-503.
37. Monti E, Sinha BK. Potentiation of doxorubicin cytotoxicity by (+)-1,2-bis-(3,5-dioxopiperazin-1-yl) propane (ICRF-187) in human leukemic HL-60 cells. Cancer Commun 1990; 2: 145-9.
38. Tomkins CE, Edwards SN, Tolkovsky AM. Apoptosis is induced in post-mitotic rat sympathetic neurons by arabinosides and topoisomerase II inhibitors in the presence of NGF. J Cell Sci 1994; 107: 1499-507.
39. Hochster H, Liebes L, Wadler S, et al. Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicin. J Natl Cancer Inst 1992; 84: 1725-30.
40. Verhoef V, Bell V, Filippi J. Effect of the cardioprotective agent ADR-529 (ICRF-187) on the antitumor activity of doxorubicin. Proc Am Ass Cancer Res 1988; 29: 273.
41. Woodman RJ, Cysyk RL, Kline J, Gang M, Venditti JM. Enhancement of the effectiveness of daunorubicin (NSC-82151) or adriamycin (NSC-123127) against early mouse L1210 leukemia with ICRF-159 (NSC-129943). Cancer Chemother Rep 1975; 59: 689-95.
42. Herman EH, Ferrans VJ. Timing of treatment with ICRF-187 and its effect on chronic doxorubicin cardiotoxicity. Cancer Chemother Pharmacol 1993; 32: 445-9.